Eur Rev Med Pharmacol Sci 2019; 23 (2): 708-715

DOI: 10.26355/eurrev_201901_16884

Long non-coding RNA Tubulin Alpha 4B (TUBA4B) inhibited breast cancer proliferation and invasion by directly targeting miR-19

A.-X. Liu, F. Yang, L. Huang, L.-Y. Zhang, J.-R. Zhang, R.-N. Zheng

Department of Oncology, Zhujiang Hospital, Southern Medical University, GuangZhou City, P.R. China. Zhangjiren@126.com


OBJECTIVE: Long non-coding RNA (lncRNA) is a significant member of the non-coding RNA family. New evidence has shown that it plays a pivotal role in the processes of tumor genesis and development. According to previous verification, the lncRNA Tubulin Alpha 4B (TUBA4B) is a tumor-associated molecule, but how TUBA4B expresses and functions in breast cancer is still not clear.

PATIENTS AND METHODS: We conducted this study to examine what expression and biological role TUBA4B plays in breast cancer. The expression of TUBA4B was measured in breast cancer samples and cell lines. CCK8 assays and transwell assays were used for evaluating the effects of TUBA4B on breast cancer cell proliferation and invasion. Luciferase reporter assays were used for identifying the direct target of TUBA4B.

RESULTS: According to the results, TUBA4B was largely downregulated in breast cancer samples and cell lines. The functional analysis demonstrated that breast cancer cells proliferation and invasion could be inhibited by overexpression of TUBA4B. The results of Luciferase reporter assays indicated that TUBA4B directly targeted miR-19, which could rescue the effects of TUBA4B on breast cancer cells.

CONCLUSIONS: It is suggested that TUBA4B was downregulated in breast cancer and suppressed proliferation and invasion of breast cancer by targeting miR-19.

Free PDF Download

To cite this article

A.-X. Liu, F. Yang, L. Huang, L.-Y. Zhang, J.-R. Zhang, R.-N. Zheng
Long non-coding RNA Tubulin Alpha 4B (TUBA4B) inhibited breast cancer proliferation and invasion by directly targeting miR-19

Eur Rev Med Pharmacol Sci
Year: 2019
Vol. 23 - N. 2
Pages: 708-715
DOI: 10.26355/eurrev_201901_16884